FDA ·
The FDA Drug Shortage Staff maintains a public database of drug products in shortage. Shortage designation is based on whether total supply from all manufacturers meets total demand. A product enters the list when a manufacturer notifies FDA of supply disruption or when FDA identifies a shortage through other means, and it is removed when supply is restored. Importantly, the shortage designation is a factual determination about aggregate supply, not about price or patient access. This distinction has been central to many 2025–2026 debates about whether certain GLP-1s remain 'practically' in shortage even when formally resolved.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.